REGN

Regeneron Pharmaceuticals (REGN)

About Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Details

Daily high
$783.10
Daily low
$753.69
Price at open
$782.78
52 Week High
$1,211.20
52 Week Low
$753.69
Market cap
83.2B
Dividend yield
0.00%
Volume
1.4M
Avg. volume
875,811
P/E ratio
18.73

Regeneron Pharmaceuticals News

Details

Daily high
$783.10
Daily low
$753.69
Price at open
$782.78
52 Week High
$1,211.20
52 Week Low
$753.69
Market cap
83.2B
Dividend yield
0.00%
Volume
1.4M
Avg. volume
875,811
P/E ratio
18.73